STT3A

Across TCGA pan-cancer cohorts, STT3A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated STT3A data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher STT3A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated STT3A expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where STT3A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.984	0.807	<.001	44	view →
HNSC	DFS	Quartile	All	0.910	0.677	.001	31	view →
CCRCC	DFS	Median	III,IV	0.518	0.828	.003	25	view →
PDAC	OS	Tertile	All	0.429	0.616	.010	14	view →
LSCC	DFS	Median	All	0.907	0.464	.009	2	view →
UCEC	DFS	Tertile	All	0.864	0.972	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

STT3A–LUAD (DFS)

Open the LUAD breakdown →